Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors

NCT04596033 is registered in ClinicalTrials.gov with Genocea Biosciences, Inc. as lead sponsor.

NCT NCT04596033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04596033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Lead sponsor
Genocea Biosciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 11, 2020
Completion date
June 27, 2022
Enrollment
49 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

anal squamous cell carcinoma, cutaneous squamous cell carcinoma, melanoma, merkel cell carcinoma, non-small cell lung cancer, renal cell carcinoma, small-cell lung cancer, squamous cell carcinoma of head and neck, urothelial carcinoma